Jazz Pharmaceuticals plc (JAZZ) is a Biotechnology company in the Healthcare sector, currently trading at $201.06. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of JAZZ = $541.89 (+169.5% from the current price, the stock appears undervalued). Analyst consensus target is JAZZ = $208 (+3.4% upside).
Valuation: JAZZ trades at a trailing Price-to-Earnings (P/E) of -33.3 (S&P 500 average ~25).
Financials: revenue is $4.3B, +5.3%/yr average growth. Net income is $356M (loss), growing at +55.1%/yr. Net profit margin is -8.3% (negative). Gross margin is 88.2% (+3 pp trend).
Balance sheet: total debt is $5.4B against $4.3B equity (Debt-to-Equity (D/E) ratio 1.26, moderate). Current ratio is 1.86 (strong liquidity). Debt-to-assets is 46.5%. Total assets: $11.7B.
Analyst outlook: 41 / 47 analysts rate JAZZ as buy (87%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 83/100 (Pass), Past 50/100 (Partial), Health 50/100 (Partial), Moat 80/100 (Pass), Future 76/100 (Pass), Income 10/100 (Fail).
